Les acteurs du numérique pourraient-ils tuer Big Pharma ? Genetic Programmers Are the Next Startup Millionaires. A two-year-old company developing molecular “logic” for cancer treatment has been snapped up for $175 million by Gilead Sciences amid a surge of interest in ways to battle disease using engineered immune cells. The pricey acquisition of Cell Design Labs, a startup that’s produced no drugs, signals an ongoing acquisition frenzy around one of cancer medicine’s most promising approaches.
Cell Design Labs, founded by University of California, San Francisco, synthetic biologist Wendell Lim, creates “programs” to install inside T cells, the killer cells of the immune system, giving them new abilities. Beginning in August, the U.S. approved two novel treatments in which a person’s T cells are genetically reprogrammed to seek and destroy cancer cells. Known as “CAR-T,” the treatments are both revolutionary and hugely expensive. A single dose is priced at around $500,000 but often results in a cure. Gilead quickly paid $12 billion to acquire Kite Pharma, maker of one of those treatments.
Stilla Technologies révolutionne les diagnostics médicaux - Les Echos. Turning big promises with 'big data' in agriculture into farmer and consumer benefits. Making biotechnology interactive with games, remote-control labs. In his third and most far-reaching project, Riedel-Kruse and his team created a robotic biology lab capable of carrying out remote-controlled experiments. “We call these robots Biotic Processing Units, or BPUs,” said Zahid Hossain, the Stanford doctoral student who worked with Riedel-Kruse on this third project. Creation of a remote lab “A BPU is an instrument that can hold and repeatedly stimulate biological materials, such as cells, and measure the biological responses,” Hossain said.
“It is the key enabler of interactive biotechnology.” The remote lab was presented at the conference in South Korea. Hossain constructed this prototype BPU by using LEGO Mindstorms, a kit for making robots, to create a liquid-handling robot. We are enabling people to interact with biological materials and perform experiments the way they interact with computers today. The researchers incorporated this BPU as a lab component in a graduate-level theory class. A micro-aquarium. 6 Things the Digital Revolution already Disrupted in the Biotech Industry - Labiotech.eu. 2 weeks ago, I was at NOAH15 in Berlin, one of the biggest European events on Digital, gathering key opinion leaders such as Eric Schmidt from Google or Ariana Huffington, founder of the Huffington Post. They all talked about the impact of the recent digital wave, internet and the post-pc area on different industries.
Biotech wasn’t represented – as, e-health doesn’t quite encompass my definition of Biotech – and by listening to the speakers, I asked myself, what has the digital wave disrupted in the Biotech industry? Listed below are the 6 things that changed in the Biotech field over the last quarter-century. 1. Big data is a reality In 2015, you can access so much data: All the sequenced genes are available on NCBI,All the proteins on UniProt,A lot of patient information is available, take a look at the British NHSDeals and companies in the Biotech space are gaining in visibility thanks to Biocentury, Biotechgate or Labiotechmap.com Data exploitation is now much easier. 2. 3. 4. 5. 6. Review: the Emerging Field of Bioluminescence - Labiotech.eu. Thanks to the synthetic biology revolution, bioluminescence is now moving from a curious natural trait to an interesting research field that could soon arrive to the market.
Bioluminescence’s impulsors aim at replacing electric lighting. Sounds good, but which are the most advanced projects right now? Will bioluminescence really have an impact on the lighting market and when? Bioluminescence, the production and emission of light by a living organism, occurs widely in nature. This natural property was first observed hundreds of years ago. The principal chemical reaction in bioluminescence involves the light-emitting pigment luciferin and the enzyme luciferase.
After the invention of gene cloning in the 80s, it is now exploited in bio-related research. This great research tool is now moving to the market. The most advanced European project using bioluminescence is the one carried out by the French startup Glowee. But who else is trying to bring bioluminescence to the market? After the Biofuel Fail, Does Synthetic Biology Have a Future? | Bryan Johnson. Last month, Newsweek tweeted: "Synbio was going to save the world.
Now it's being used to make vanilla flavoring. " Synthetic biology (synbio), for the uninitiated, uses organisms and designs from nature to engineer new tools. The Newsweek article details the synthetic biology industry's failure to produce biofuels from pond scum on a large scale, and how it has now pivoted to produce flavors and fragrances.
Synthetic biology won't stop an asteroid from hitting Earth, but making vanilla flavoring is a first step toward a new industrial era powered by biology. Almost everything we use daily -- from food to clothing to toys -- relies on decades- to centuries-old ingredients and production processes. Microorganisms can make many of the same ingredients as the traditional industrialization process but with less energy and waste and without relying on petroleum derivatives. Biologists are the engineers of the future. And in many cases, these efforts are already under way. Bientôt de l'essence fabriquée à partir de végétaux ? Et si demain nos voitures roulaient grâce à nos déchets issus des tontes de pelouse, du taillage des haies ou des résidus agricoles ou forestiers ?
C'est ce qu'espère l'entreprise champenoise Global Bioenergies. Cette dernière a mis au point un procédé permettant de transformer la matière végétale en isobutène. Une molécule clef de l'industrie pétrochimique à partir de laquelle il est possible de fabriquer de nombreux composés chimiques et notamment des additifs pour carburants, mais aussi du kérosène, des lubrifiants. Certains de ses composants entrent aussi dans la fabrication du plexiglas, des caoutchoucs et des peintures acryliques. Arbre des produits dérivés de l'Isobutène. ©Global Biotechnologies "L’isooctane est un additif actuellement utilisé pour améliorer la qualité de l’essence et qui pourrait également servir de carburant à part entière" explique l'entreprise sur son site.
Présentation de l'unité de traitement des végétaux. OGM. OpenPlant: Open Technologies for Plant Synthetic Biology - SynBioBeta. Why is Plant Synthetic Biology Important? Plant synthetic biology has great potential to improve sustainable bioproduction of globally important products; from foodstuffs to fibres to drugs. Advantages of plants over engineered microbes include their worldwide cultivation, their harvest on a giga-tonne scale and the existing precedent for genetically modified crops in many parts of the world. In addition to these applied benefits, plants raise interesting scientific questions and technical challenges around engineering pathways and interactions in multi-cellular, differentiating and developing organisms, adding complexity to current microbial experiments.
Plant synthetic biology is a young field and requires the development of tools and techniques to deal with additional complexity, such as improved genome editing, DNA synthesis and assembly at chromosomal or genomic scales. Right: Image of Marchantia Latest Blog Posts Jenny Molloy Latest posts by Jenny Molloy (see all) Home. Glowee, l'éclairage bioluminescent. The Acceleration of Acceleration: How The Future Is Arriving Far Faster Than Expected. The Acceleration of Acceleration: How The Future Is Arriving Far Faster Than Expected This article co-written with Ken Goffman. One of the things that happens when you write books about the future is you get to watch your predictions fail.
This is nothing new, of course, but what’s different this time around is the direction of those failures. Used to be, folks were way too bullish about technology and way too optimistic with their predictions. Flying cars and Mars missions being two classic—they should be here by now—examples. The Jetsons being another. But today, the exact opposite is happening. Take Abundance. And we were wrong. Just three years later, Google went on a buying spree, purchasing eight different robotics companies in less than six months, Amazon decided it was time to get into the drone delivery (aka flying robots) business, and Rethink Robotics released Baxter (a story explored in my new release Bold), the first user-friendly industrial robot to hit the market.
2045 Initiative. The 2045 Initiative is a nonprofit organization that develops a network and community of researchers in the field of life extension.  It was founded by Russian entrepreneur Dmitry Itskov, in February 2011 with the participation of Russian specialists in the field of neural interfaces, robotics, artificial organs and systems. The main goal of the 2045 Initiative, as stated on site, is "to create technologies enabling the transfer of an individual’s personality to a more advanced non-biological carrier, and extending life, including to the point of immortality.
We devote particular attention to enabling the fullest possible dialogue between the world’s major spiritual traditions, science and society". Future prospects Avatar Project One of the featured life-extension projects is to design an artificial humanoid body (called Avatar) and an advanced brain–computer interface system. Avatar A Avatar B Avatar C Avatar D A hologram-like avatar. Reception Andras Forgacs: Leather and meat without killing animals.
Paul Stamets: 6 ways mushrooms can save the world. Hoffmann-La Roche. Un article de Wikipédia, l'encyclopédie libre. F. Hoffmann-La Roche AG Logo de Hoffmann-La Roche Roche (F. La société présente depuis 2004 deux sections parallèles, le secteur pharmaceutique et le secteur diagnostic. La société est présente commercialement dans 150 pays. Histoire[modifier | modifier le code] La société a été fondée le 1er octobre 1896 par Fritz Hoffmann-La Roche. En 1933, Roche lance la synthèse de la vitamine C grâce aux travaux de Tadeusz Reichstein (Prix Nobel en 1950).
En 1972, Givaudan, une de ses filiales, est mise en cause dans l'affaire du talc Morhange qui tua 36 bébés et en intoxiqua plus d'une centaine. En 1989, Roche est restructuré avec la fondation de Roche Holding AG. En 1994, Roche acquiert du groupe pharmaceutique américain Syntex Corporation, de Palo Alto (Californie) qui deviendra Roche Bioscience. Boîte de Tamiflu produite par Roche En 1999, la Food and Drug Administration autorise le Tamiflu efficace contre la grippe aviaire de type H5N1.
News Highlights:Holiday Stress May Up the Need for Reward but Don’t Expect Any Joy. Feeling stressed may prompt you to go to great lengths to satisfy an urge for a drink or sweets, but you’re not likely to enjoy the indulgence any more than someone who is not stressed and has the same treat just for pleasure, according to a study (“Stress Increases Cue-Triggered `Wanting” for Sweet Reward in Humans”) published in the Journal of Experimental Psychology: Animal Learning and Cognition. "Most of us have experienced stress that increases our craving for rewarding experiences, such as eating a tasty bar of chocolate, and it can make us invest considerable effort in obtaining the object of our desire, such as running to a convenience store in the middle of the night," said lead author Eva Pool, a doctoral student at the University of Geneva.
"But while stress increases our desire to indulge in rewards, it does not necessarily increase the enjoyment we experience. "